Skip to main content
Erschienen in: Strahlentherapie und Onkologie 9/2013

01.09.2013 | Original article

Outcome after neoadjuvant chemoradiation and correlation with nutritional status in patients with locally advanced pancreatic cancer

verfasst von: P. Naumann, MD, D. Habermehl, MD, T. Welzel, MD, J. Debus, MD PhD, S.E. Combs, MD

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 9/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Cancer patients commonly suffer from weight loss since rapid tumor growth can cause catabolic metabolism and depletion of energy stores such as abdominal fat. In locally advanced pancreatic cancer this is even more pronounced due to abdominal pain, fatigue, nausea or malnutrition. In the present article, we quantify this frequently observed weight loss and assess its impact on outcome and survival.

Methods

Data on demographics, biometrics, toxicity and survival were collected for the last 100 patients treated with neoadjuvant chemoradiation for locally advanced pancreatic cancer at our department (45.0 Gy and boost up to 54.0 Gy plus concurrent and subsequent gemcitabine), and the subcutaneous fat area at the umbilicus level was measured by computer tomography before and after chemoradiation.

Results

After chemoradiation, patients showed a highly statistically significant weight loss and reduction of the subcutaneous fat area. We could determine a very strong correlation of subcutaneous fat area to patient BMI. By categorizing patients according to their BMI based on the WHO classification as slender, normal, overweight and obese, we found improved but not statistically significant survival among obese patients. Accordingly, patients who showed less weight loss tended to survive longer.

Conclusions

In this study, patients with pancreatic cancer lost weight during chemoradiation and their subcutaneous fat diminished. Changes in subcutaneous fat area were highly correlated with patients’ BMI. Moreover, obese patients and patients who lost less weight had an improved outcome after treatment. Although the extent of weight loss was not significantly correlated with survival, the observed trend warrants greater attention to nutritional status in the future.
Literatur
1.
2.
Zurück zum Zitat Gillen S, Schuster T, Meyer Zum Buschenfelde C et al (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7:e1000267PubMedCrossRef Gillen S, Schuster T, Meyer Zum Buschenfelde C et al (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7:e1000267PubMedCrossRef
3.
Zurück zum Zitat Satoi S, Yanagimoto H, Toyokawa H et al (2009) Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer. Pancreas 38:282–288PubMedCrossRef Satoi S, Yanagimoto H, Toyokawa H et al (2009) Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer. Pancreas 38:282–288PubMedCrossRef
4.
Zurück zum Zitat Habermehl D, Kessel K, Welzel T et al (2012) Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. Radiat oncol 7:28PubMedCrossRef Habermehl D, Kessel K, Welzel T et al (2012) Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. Radiat oncol 7:28PubMedCrossRef
5.
Zurück zum Zitat Tinkl D, Grabenbauer GG, Golcher H et al (2009) Downstaging of pancreatic carcinoma after neoadjuvant chemoradiation. Strahlenther Onkol 185:557–566PubMedCrossRef Tinkl D, Grabenbauer GG, Golcher H et al (2009) Downstaging of pancreatic carcinoma after neoadjuvant chemoradiation. Strahlenther Onkol 185:557–566PubMedCrossRef
6.
Zurück zum Zitat Brunner T (2012) Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. Strahlenther Onkol 188:366–367PubMedCrossRef Brunner T (2012) Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. Strahlenther Onkol 188:366–367PubMedCrossRef
7.
Zurück zum Zitat Klautke G, Brunner TB (2008) Radiotherapy in pancreatic cancer. Strahlenther Onkol 184:557–564PubMedCrossRef Klautke G, Brunner TB (2008) Radiotherapy in pancreatic cancer. Strahlenther Onkol 184:557–564PubMedCrossRef
8.
Zurück zum Zitat Combs SE, Werner J (2013) Resection plus adjuvant chemotherapy improves survival in advanced pancreatic adenocarcinoma. Strahlenther Onkol 189:163–165PubMedCrossRef Combs SE, Werner J (2013) Resection plus adjuvant chemotherapy improves survival in advanced pancreatic adenocarcinoma. Strahlenther Onkol 189:163–165PubMedCrossRef
9.
Zurück zum Zitat Williams TK, Rosato EL, Kennedy EP et al (2009) Impact of obesity on perioperative morbidity and mortality after pancreaticoduodenectomy. J Am Coll Surg 208:210–217PubMedCrossRef Williams TK, Rosato EL, Kennedy EP et al (2009) Impact of obesity on perioperative morbidity and mortality after pancreaticoduodenectomy. J Am Coll Surg 208:210–217PubMedCrossRef
10.
Zurück zum Zitat Fleming JB, Gonzalez RJ, Petzel MQ et al (2009) Influence of obesity on cancer-related outcomes after pancreatectomy to treat pancreatic adenocarcinoma. Arch Surg 144:216–221PubMedCrossRef Fleming JB, Gonzalez RJ, Petzel MQ et al (2009) Influence of obesity on cancer-related outcomes after pancreatectomy to treat pancreatic adenocarcinoma. Arch Surg 144:216–221PubMedCrossRef
11.
Zurück zum Zitat Gaujoux S, Torres J, Olson S et al (2012) Impact of obesity and body fat distribution on survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg Oncol 19(9):2908–2916PubMedCrossRef Gaujoux S, Torres J, Olson S et al (2012) Impact of obesity and body fat distribution on survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg Oncol 19(9):2908–2916PubMedCrossRef
12.
Zurück zum Zitat Pai PC, Chuang CC, Tseng CK et al (2012) Impact of pretreatment body mass index on patients with head-and-neck cancer treated with radiation. Int J Radiat Oncol Biol Phys 83:e93–e100PubMedCrossRef Pai PC, Chuang CC, Tseng CK et al (2012) Impact of pretreatment body mass index on patients with head-and-neck cancer treated with radiation. Int J Radiat Oncol Biol Phys 83:e93–e100PubMedCrossRef
13.
Zurück zum Zitat Yoshizumi T, Nakamura T, Yamane M et al (1999) Abdominal fat: standardized technique for measurement at CT. Radiology 211:283–286PubMed Yoshizumi T, Nakamura T, Yamane M et al (1999) Abdominal fat: standardized technique for measurement at CT. Radiology 211:283–286PubMed
14.
Zurück zum Zitat Chatterjee D, Katz MH, Rashid A et al (2012) Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. Cancer 118:3182–3190PubMedCrossRef Chatterjee D, Katz MH, Rashid A et al (2012) Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. Cancer 118:3182–3190PubMedCrossRef
15.
Zurück zum Zitat Chatterjee D, Katz MH, Rashid A et al (2012) Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. Am J Surg Pathol 36:409–417PubMedCrossRef Chatterjee D, Katz MH, Rashid A et al (2012) Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. Am J Surg Pathol 36:409–417PubMedCrossRef
16.
Zurück zum Zitat Chatterjee D, Rashid A, Wang H et al (2012) Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy. Am J Surg Pathol 36:552–559PubMedCrossRef Chatterjee D, Rashid A, Wang H et al (2012) Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy. Am J Surg Pathol 36:552–559PubMedCrossRef
17.
Zurück zum Zitat Morana G, Cancian L, Pozzi Mucelli R, Cugini C (2010) Staging cancer of the pancreas. Cancer Imaging 10 Spec no A:S137–S141CrossRef Morana G, Cancian L, Pozzi Mucelli R, Cugini C (2010) Staging cancer of the pancreas. Cancer Imaging 10 Spec no A:S137–S141CrossRef
18.
Zurück zum Zitat Snell-Bergeon JK, Hokanson JE, Kinney GL et al (2004) Measurement of abdominal fat by CT compared to waist circumference and BMI in explaining the presence of coronary calcium. Int J Obes Relat Metab Disord 28:1594–1599PubMedCrossRef Snell-Bergeon JK, Hokanson JE, Kinney GL et al (2004) Measurement of abdominal fat by CT compared to waist circumference and BMI in explaining the presence of coronary calcium. Int J Obes Relat Metab Disord 28:1594–1599PubMedCrossRef
19.
Zurück zum Zitat Bing C (2011) Lipid mobilization in cachexia: mechanisms and mediators. Curr Opin Support Palliat Care 5:356–360PubMedCrossRef Bing C (2011) Lipid mobilization in cachexia: mechanisms and mediators. Curr Opin Support Palliat Care 5:356–360PubMedCrossRef
20.
Zurück zum Zitat Aslani A, Roach PJ, Smith RC (2012) Long-term changes in body composition after pancreaticoduodenectomy. ANZ J Surg 82:173–178PubMedCrossRef Aslani A, Roach PJ, Smith RC (2012) Long-term changes in body composition after pancreaticoduodenectomy. ANZ J Surg 82:173–178PubMedCrossRef
21.
Zurück zum Zitat Riess H, Pelzer U, Hilbig A et al (2008) Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer 8:361PubMedCrossRef Riess H, Pelzer U, Hilbig A et al (2008) Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer 8:361PubMedCrossRef
22.
Zurück zum Zitat Tyrrel RT, Montemayor KA, Bernardino ME (1990) CT density of mesenteric, retroperitoneal, and subcutaneous fat in cirrhotic patients: comparison with control subjects. AJR Am J Roentgenol 155:73–75PubMedCrossRef Tyrrel RT, Montemayor KA, Bernardino ME (1990) CT density of mesenteric, retroperitoneal, and subcutaneous fat in cirrhotic patients: comparison with control subjects. AJR Am J Roentgenol 155:73–75PubMedCrossRef
23.
Zurück zum Zitat Wolff HA, Conradi LC, Schirmer M et al (2011) Gender-specific acute organ toxicity during intensified preoperative radiochemotherapy for rectal cancer. Oncologist 16:621–631PubMedCrossRef Wolff HA, Conradi LC, Schirmer M et al (2011) Gender-specific acute organ toxicity during intensified preoperative radiochemotherapy for rectal cancer. Oncologist 16:621–631PubMedCrossRef
24.
Zurück zum Zitat Rabinovitch R, Grant B, Berkey BA et al (2006) Impact of nutrition support on treatment outcome in patients with locally advanced head and neck squamous cell cancer treated with definitive radiotherapy: a secondary analysis of RTOG trial 90–03. Head Neck 28:287–296PubMedCrossRef Rabinovitch R, Grant B, Berkey BA et al (2006) Impact of nutrition support on treatment outcome in patients with locally advanced head and neck squamous cell cancer treated with definitive radiotherapy: a secondary analysis of RTOG trial 90–03. Head Neck 28:287–296PubMedCrossRef
Metadaten
Titel
Outcome after neoadjuvant chemoradiation and correlation with nutritional status in patients with locally advanced pancreatic cancer
verfasst von
P. Naumann, MD
D. Habermehl, MD
T. Welzel, MD
J. Debus, MD PhD
S.E. Combs, MD
Publikationsdatum
01.09.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 9/2013
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-013-0393-3

Weitere Artikel der Ausgabe 9/2013

Strahlentherapie und Onkologie 9/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.